FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

OIPE 553 MAR 05 2002 PATENT & TRADEMARK OFFICE

RECEIVED MAR 14 2002 TECH CENTER 1600/2900

ATTY. DOCKET NO.	APPLICATION NO.
ELITRA.009A	09/741,669
APPLICANT: Forsyth, et al.	
FILING DATE: December 19, 2000	GROUP ~~1645~~ 1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	6,348,582 B1	02/19/02	Black, et al.			
	2	6,348,582	02/19/02	Black, et al. (Printout of Sequence Listing)			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	3	EP 0 786 519 A2	07/30/97	EPO				
	4	EP 0 786 519 A3	07/30/97	EPO				
	5	WO 00/61793	10/19/00	PCT				
	6	WO 01/49721 A2	07/12/01	PCT				

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	7	Akerley, et al., "A genome-scale analysis for identification of genes required for growth or survival of *Haemophilus influenzae*," *PNAS*, 99(2):966-971 (2002).
	8	Blattner, et al., "Escherichia coli K12 MG1655 section 101 of 400 of the complete genome," Database accession no. AE000211, XP002181472.
	9	Blattner, et al., "Escherichia coli K12 MG1655 section 305 of 400 of the complete genome," Database accession no. AE000415, XP002181474.
	10	Blattner, et al., "Hypothetical 79.5 kDa protein in MRCA-PCKA intergenic region (0711)," Database accession no. P45800, XP002181475.
	11	Blattner, et al., "Hypothetical protein YCFS precursor," Database accession no. P75954, XP002181473.
	12	De Backer, et al., "An antisense-based functional genomics approach for identification of genes critical for growth of *Candida albicans*," *Nature Biotechnology*, 19:235-241 (2001).
	13	Lancy, et al., "Nucleotide Sequences of *dnaE*, the Gene for the Polymerase Subunit of DNA Polymerase III in *Salmonella typhimurium*, and a Variant That Facilitates Growth in the Absence of Another Polymerase Subunit," *Journal of Bacteriology*, 171(10):5581-5586 (1989).
	14	Oshima, et al., "A 718-kb DNA Sequence of the *Escherichia coli* K-12 Genome Corresponding to the 12.7-28.0 min Region on the Linkage Map," *DNA Research*, 3:137-155 (1996).
	15	Oshima, et al.. "*Escherichia coli* genomic DNA (25.2-25.6 min)," Database accession no. D90747, XP002181476 (1996).
	16	Plunkett, et al., "*Escherichia coli* K-12 chromosomal region from 67.4 to 76.0 minutes," Database accession no. U18997, XP002181477.

S:\DOCS\DOH\DOH-6492.DOC:dmb
022102

EXAMINER	DATE CONSIDERED
	9/6/2002

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

15

SHEET 1 OF 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.009A	APPLICATION NO. 09/741,669
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Forsyth, et al.	
	FILING DATE December 19, 2000	GROUP 1634

RECEIVED JUL 03 2002 TECH CENTER 1600/2900

OIPE JUN 28 2002 PATENT & TRADEMARK

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
✓	1	6,228,579 B1	05/08/01	Zyskind, et al.			
✓	2	6,228,588 B1	05/08/01	Benton, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
✓	3	Good, et al. 1998. Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. *Proc. Natl. Acad. Sci. USA*, 95:2073-2076.

S:\DOCS\DOH\DOH-6826.DOC:dmb
062402

EXAMINER	DATE CONSIDERED 9/6/2002

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.009A	APPLICATION NO. 09/741,669
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Forsyth, et al.	
	FILING DATE December 19, 2000	GROUP ~~1645~~ 1634

OIPE JC
AUG 0 2 2001
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
W	1	4,622,297	11/11/86	Kappner, et al.			
	2	4,906,742	3/6/90	Young et al.			
	3	4,980,281	12/25/90	Housey, et al.			
	4	5,190,931	03/02/93	Inouye			
	5	5,208,149	05/04/93	Inouye, et al.			
	6	5,266,464	11/30/93	Housey, et al.			
	7	5,272,065	12/21/93	Inouye, et al.			
	8	5,569,588	12/09/96	Ashby, et al.			
	9	5,585,277	12/17/96	Bowie, et al.			
	10	5,679,523	10/21/97	Li et al.			
	11	5,688,655	11/08/97	Housey, et al.			
	12	5,756,305	05/26/98	Timberlake, et al.			
	13	5,821,076	10/13/98	Timberlake, et al.			
	14	5,846,772	12/8/98	Hodgson et al.			
	15	5,854,020	12/29/98	Hodgson et al.			
	16	5,858,709	1/12/99	Hodgson et al.			
	17	5,869,290	2/9/99	Freeman et al.			
	18	5,877, 007	03/02/99	Housey, et al.			
	19	5,882,643	3/16/99	Lonetto			
	20	5,885,572	3/23/99	Gentry e t al.			
	21	5,891,667	4/6/99	Hodgson et al.			
	22	5,910,414	6/8/99	Gwynn et al.			
	23	5,955,275	9/21/99	Kamb			
	24	5,965,352	10/12/99	Stoughton, et al.			
	25	6,015,669	01/18/00	Holden			
	26	6,020,121	2/1/00	Bao et al.			
	27	6,037,123	3/14/00	Benton et al.			
	28	6,174,678	01/16/01	Menzel, et al.			
↓	29	6,248,525 B1	06/19/01	Nilsen			

EXAMINER	DATE CONSIDERED 9/6/2002

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

OIPE JC14 AUG 0 2 2001 PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.	APPLICATION NO.
ELITRA.009A	09/741,669
APPLICANT: Forsyth, et al.	
FILING DATE: December 19, 2000	GROUP ~~1645~~ 1634

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
W	30	0816511 A1	1/7/98	EP				
	31	0837142 A1	4/22/98	EP				
	32	0891984 A2	1/20/99	EP				
	33	0889123 A2	1/7/99	EP				
	34	0889129 A2	1/7/99	EP				
	35	0892056 A2	1/20/99	EP				
	36	0892064 A2	1/20/99	EP				
	37	0894806 A1	2/3/99	EP				
	38	0897008 A2	2/17/99	EP				
	39	0906959 A2	4/7/99	EP				
	40	0905247 A2	3/31/99	EP				
	41	0900845 A2	3/10/99	EP				
	42	WO 95/06132	03/02/95	PCT				
	43	WO 96/23075	08/01/96	PCT				
	44	WO 96/40979	12/19/96	PCT				
	45	WO 97/11690	04/03/97	PCT				
	46	WO 97/16177	5/9/97	PCT				
	47	WO 97/23642	07/03/97	PCT				
	48	WO 97/27212	7/31/97	PCT				
	49	WO 97/27213	7/31/97	PCT				
	50	WO 97/37026	10/9/97	PCT				
	51	WO 97/40851	11/6/97	PCT				
	52	WO 97/42210	11/13/97	PCT				
	53	WO 97/48822	12/24/97	PCT				
	54	WO 98/03533	01/29/98	PCT				
	55	WO 98/19162	5/7/98	PCT				
	56	WO 98/20161	5/14/98	PCT				
✓	57	WO 98/21366	5/22/98	PCT				

EXAMINER [signature] DATE CONSIDERED 9/6/2002

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

OIPE JC14 AUG 02 2001 PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.	APPLICATION NO.
ELITRA.009A	09/741,669
APPLICANT: Forsyth, et al.	
FILING DATE: December 19, 2000	GROUP ~~1645~~ 1634

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	58	WO 98/42854	10/1/98	PCT				
W	59	WO 98/44135	10/8/98	PCT				
	77	WO 99/02673	01/21/99	PCT				
	60	WO 99/06839	2/11/99	PCT				
	61	WO 99/23244	05/14/99	PCT				
	62	WO 99/26651	6/3/99	PCT				
	63	WO 99/27074	6/3/99	PCT				
	64	WO 99/27128	6/3/99	PCT				
	65	WO 99/28508	6/10/99	PCT				
	66	WO 99/29837	6/17/99	PCT				
	67	WO 99/35494	7/15/99	PCT				
	68	WO 99/36554	07/22/99	PCT				
	69	WO 99/43338	09/02/99	PCT				
	70	WO 99/49888	10/07/99	PCT				
	71	WO 99/50462	10/07/99	PCT				
	72	WO 99/52926	10/21/99	PCT				
	73	WO 99/53079	10/21/99	PCT				
	74	WO 99/55729	11/04/99	PCT				
	75	WO 99/61452	12/02/99	PCT				
	76	WO 00/34481	06/15/00	PCT				
	78	WO 01/09164 A2	02/08/01	PCT				
	79	WO 01/11081 A2	02/15/01	PCT				
	80	WO 01/49775 A2	07/12/01	PCT				

EXAMINER: W L M DATE CONSIDERED: 9/6/2002

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.009A	APPLICATION NO. 09/741,669
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Forsyth, et al.	
	FILING DATE December 19, 2000	GROUP ~~1645~~ 1634

OIPE AUG 0 2 2001 PATENT & TRADEMARK OFFICE

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	81	Armstrong, et al., (1975), Essential Genes in the *metB-malB* Region of *Escherichia coli* K12, *J. Bacteriol.*, 126: 48-55.
	82	Austin, A. E., et al., *Journal of Bacteriology*, 172:5312-5325, 1990, "Genetic Analysis of Lipopolysaccharide Core Biosynthesis by *Escherichia coli* k12 Insertion Mutagenesis of the RFA Locus."
	83	Biswas, E.E. and Biswas, S.B., "Mechanism and DnaB Helicase of *Escherichia coli:* Structural Domains Involved in ATP Hydrolysis, DNA Binding, and Oligomerization," BIOCHEM. 38:10919-10928 (1999).
	84	Blattner, et al., *Science*, 277:1453-1474, 1997, "The Complete Genome Sequence of Escherichia Coli K-12."
	85	Cotrim, et al., *Journal of Biological Chemistry*, 274(53):37723-37730, 1999, "Isolation of Genes Mediating Resistance to Inhibitors of Nucleoside and Ergosterol Metabolism in *Leishmania* by Overexpression/Selection."
	86	den Hollander, J.G., et al., "Synergism Between Tobramycin and Ceftazidime Against a Resistant Pseudomonas Aeruginosa Strain, Tested in an In Vitro Pharmacokinetic Model," ANTIMICROBIA AGENTS & CHEMOTHERAPY 41:95-110 (1997).
	87	Fukuoka, T., et al., "Combination Effect Between Panipenem and Vancomycin on Highly Methicillin-Resistant Staphylococcus Aureus," JAPAN. J. ANTIBIO. 50:411-419 (1997).
	88	Gabryelewicz, A., et al., "Multicenter Evaluation of Dual-Therapy (Omeprazol and Amoxycillin) for *Helicobacter Pylori*-Associated Duodenal and Gastric Ulcer (Two Years of the Observation)," J. PHYSIOL. PHARMACOL. 48 Suppl. 4:93-105 (1997).
	89	Gudkov, A.V., and Roninson, I.B., "Isolation of Genetic Suppressor Elements (GSEs) from Random Fragment cDNA Libraries in Retroviral Vectors," METHODS IN MOLEC. BIOL., Vol. 69 cDNA Library Protocols, Edited by I.G. Cowell and C.A. Austin, Humana Press, Inc., Totowa, N.Y.
	90	Gutmann, L., et al., "Involvement of Pencillin-Binding Protein 2 with other Pencillin-Binding Proteins in Lysis of *Escherichia coli* by some Beta-Lactam Antibiotics Alone and in Synergistic Lytic Effect of Amdinocillin (Mecillinam)," ANTIMICROBIAL AGENTS & CHEMOTHERAPY 30:906-912 (1986).
	91	Hiasa, H. and Marians, K.J., "Initiation of Bidirectional Replication at the Chromosomal Origin is Directed by the Interaction Between Helicase and primase," J. BIOL. CHEM. 274:27244-27248 (1999).
	92	Holzmayer, T.A., et al., "Isolation of Dominant Negative Mutants and Inhibitory Antisense RNA Sequences by Expression Selection of Random DNA Fragments," NUCLEIC ACIDS RES. 20(4): 711-717 (Feb. 25, 1992).
	93	Ji, et al., "Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in *Staphylococcus Aureus* Infection," J. BACTERIOLOGY 181(21): 6585-6590 (November 1999).
	94	Lee, N. G., et al., *Infection and Immunity.*, 63(3):818-824, 1995, "Molecular Cloning and Characterization of tne Nontypable Haemophilus Influenzae-2019 rfaE Gene Required for Lipopolysaccharide Biosynthesis."
	95	Margolis, et al., *Antimicrobial Agents and Chemotherapy*, 44(7):1825-1831, 2000, "Peptide Deformylase in *Staphylococcus aureus*: Resistance to Inhibition Is Mediated by Mutations in the Formyltransferase Gene."
	96	Post et al., Nucleotide Sequence of the Ribosomal Protein Gene Cluster Adjacent to the Gene for RNA Polymerase Subunit Beta in Escherichia Coli", Proceedings of the National Academy of Sciences of the USA , NY, NY vol.76, no. 4, (1979) pgs. 1697-1701.
	97	San Martin, C., et al., "Three-Dimensional Reconstructions from Cryoelectron Microscopy Images Reveal an Initimate Complex Between Helicase DnaB and its Loading Partner DnaC," STRUCTURE 6:501-9 (1998).
	98	Smith, C.E., et al., "Assessment of the Synergistic Interactions of Levofloxacin and Ampicillin Against Enterococcus Faecium by the Checkerboard Agar Dilution and Time-Kill Methods," DIAGNOS. MICROBIOL. INFECT. DISEASE 27:85-92 (1997).
	99	Sutton, M.D., et al, "*Escherichia coli* DnaA Protein. The N-Terminal Domain and Loading of DnaB Helicase at the *E. coli* Chromosomal," J. BIOL. CHEM. 273:34255-62 (1998).
	100	Valvano, M. A., et al., *Journal of Bacteriology*, 182:488-497, 2000, "The rfaE Gene from *Escherichia coli* Encodes a Bifunctional Protein Involved
	101	Van Heeswijk, W. C., et al., *Molecular Microbiology*, 9:443-457, 1993, "The Genes of the Glutamine Synthetase Adenylylation Cascade are not Regulated by Nitrogen in *Escherichia coli.*"
	102	Wechsler, J.A. and Gross, J.D., "*Escherichia coli* Mutants Temperature-Sensitive for DNA Synthesis," MOL. GEN. GENETICS 113:273-284 (1971)
✓	103	Zhang, et al., *Gene*, 255:297-305, 2000, "Regulated Gene Expression in *Staphylococcus aureus* for Identifying Conditional Lethal Phenotypes and Antibiotic Mode of Action."

S:\DOCS\DOH\DOH-5512.DOC:dmb - 072401

EXAMINER	DATE CONSIDERED 9/6/2002

***EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALLY FILED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.009A	APPLICATION NO. 09/741,669
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Forsyth, et al.	
	FILING DATE December 19, 2000	GROUP ~~1648~~ 1634

RECEIVED
FEB 21 2002
TECH CENTER 1600/2900

IPE
FEB 15 2002
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
~~W~~	1	Blattner, et al., "Escherichia coli K12 MG1655 section 337 of 400 of the complete genome," Database accession no. AE000447, XP002181127. ✓
	2	Blattner, et al., "Escherichia coli K12 MG1655 section 298 of 400 of the complete genome," Database accession no. AE000408, XP002181129. ✓
	3	Burland, et al., "60 kDa inner-membrane protein," Database accession no. P25714, XP002181128. ✓
	4	Burland, et al., "E. coli; the region from 81.5 to 84.5 minutes," Database accession no. L10328, XP002181130. ✓
	5	Burland, et al., "DNA sequence and analysis of 136 kilobases of the *Escherichia coli* genome: Organizational symmetry around the origin of replication," Genomics, 16:551-561 (1993). ✓
	6	Ceretti, et al., "*Escherichia coli* spc ribosomal protein operon," Database accession no. X01563, XP002181131. ✓
	7	Plunkett, et al., "*Escherichia coli* K-12 chromosomal region from 67.4 to 76.0 minutes," Database accession no. U18997, XP002181132. ✓
	8	International Search Report from co-pending application PCT/US00/34419. ✓

S:\DOCS\DOH\DOH-6417.DOC:dmb
012502

EXAMINER	DATE CONSIDERED 9/6/2002

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.